$PM

Trump’s Surgeon General Pick Loves These 3 Tobacco Stocks

Philip Morris (PM) has a consensus 'Moderate Buy' rating with a $206.43 price target, implying 6% upside. Altria Group (MO) gained 22% YTD, with a $69.58 consensus target. British American Tobacco (BTI) has a 22% upside target amid restructuring and smokeless product growth.

Original reporting
Published Sep 17, 2026, 6:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 7:14 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Trump’s Surgeon General Pick Loves These 3 Tobacco Stocks — source image
Decision brief

The 30-second read

$PMBullishLow
01

Why it matters

No new earnings or regulatory events; the piece is a summary of existing analyst opinions.

02

Market read

Analyst target revisions provide modest guidance but lack a fresh catalyst, limiting trading relevance.

03

What to watch

Regulatory pressures and litigation risks could offset any upside.

Relevance 4/10Novelty 2/10Timing: none

Background

The article compiles recent analyst price targets and a new contract between Altria and Philip Morris.

Company-level read

Ticker impact

$PMBullishMedium confidence
Context

Analysts raise Philip Morris price target to $206.43, indicating a 6% upside.

Expected impact

Potential modest price appreciation if targets are incorporated.

Evidence & confidence

Consensus rating remains Moderate Buy; price target increase is modest and not a catalyst.

$MONeutralLow confidence
Context

Altria reports a contract with Philip Morris and a consensus price target of $69.58.

Expected impact

Limited impact; market already priced in modest upside.

Evidence & confidence

Agreement is minor and price targets show little change from current levels.

$BTIBullishMedium confidence
Context

British American Tobacco receives a consensus price target of $68.28, 22% above current price.

Expected impact

Potential upside if market re‑rates the stock.

Evidence & confidence

Target increase is notable but lacks a fresh catalyst beyond analyst sentiment.

Market effects

Tobacco sector may see modest re‑rating as analysts lift targets.

U.S. and UK tobacco stocks could see slight buying pressure.

Limited; impact confined to tobacco equities.

Counterpoint

Targets may be overly optimistic given structural decline in cigarette volumes.

Key entities

  • Philip Morris International

    Tobacco company with updated analyst price target.

  • Altria Group

    U.S. tobacco firm with a new contract and price target.

  • British American Tobacco

    Global tobacco firm with raised analyst price target.

Related articles

$PMHighAI 8/10

Why is Philip Morris International stock climbing today?

Philip Morris International (PM) stock rose 2.1% after updating its Q3 2026 EPS guidance to $2.29-$2.34, exceeding estimates. The company also raised its full-year 2026 EPS forecast to $8.35-$8.50, citing favorable currency impacts. Analysts increased price targets to $205-$225. PM's defensive profile and smoke-free products supported the stock amid broader market declines.

$PMMedAI 8/10

FDA Authorization Expands Philip Morris’s Zyn Bet, Can It Pay Off?

Philip Morris (NYSE:PM) received FDA authorization for 11 nicotine-pouch products, including higher-strength Zyn Ultra pouches. The company aims to expand its market share in the fastest-growing US nicotine category, but lower pricing and increased investment may impact profitability. The FDA cited lower harmful constituents compared to other tobacco products. PM plans to invest more in Zyn as competition intensifies, particularly against British American Tobacco's Velo brand. However, the succe

$PMMedAI 8/10

PM Looks 16.9% Overvalued on GF Value™ as Dividend Sustainabilit

Philip Morris International (NYSE: PM) raised its full-year adjusted diluted EPS forecast to $7.28-$7.43, reflecting 10.7%-12.7% growth. CEO Jacek Olczak highlighted strong pricing power and profit growth at the Barclays Global Consumer Conference. The stock, trading at $185.07, is 16.9% overvalued relative to its GF Value™ of $158.36, with a 3.16% dividend yield and a 73% payout ratio.